Interim Safety of RSVpreF Vaccination During Pregnancy
This interim analysis of an ongoing retrospective cohort study uses data from 5 US health plans to assess safety of a bivalent prefusion F subunit–based respiratory syncytial virus (RSV) vaccine administered during pregnancy during the first full RSV season after US Food and Drug Administration approval (from September 22, 2023, through June 14, 2024).
Authors
- Maria Maddalena Lino
- Nana Koram (ORCID: https://orcid.org/0000-0002-4890-6202)
- Heather Rubino
- Kristin Palmsten (ORCID: https://orcid.org/0000-0002-0134-6228)
- S B Love
- Sampada Gandhi (ORCID: https://orcid.org/0000-0001-6658-1213)
- Judith C. Maro (ORCID: https://orcid.org/0000-0001-9900-2142)
- Austin Cosgrove
- Djeneba Audrey Djibo (ORCID: https://orcid.org/0000-0003-3378-0691)
- Kuntz Jl
- Susan E. Andrade (ORCID: https://orcid.org/0000-0002-9238-793X)
- Ashley I. Michnick (ORCID: https://orcid.org/0000-0003-0304-8125)
- Katherine E. Round
- Fang Zhang
- Sarah C. MacDonald
- Sruthi Adimadhyam
- Anna E. Wentz
- Richard Platt
- Olympia E. Anastasiou
- Andrew B. Petrone
Institutions
- Harvard University (US)
- Pfizer (United States) (US)
- Wilmington University (US)
- Oaks Hospital (GB)
- Harvard Pilgrim Health Care (US)
- Kaiser Permanente Center for Health Research (US)
- HealthPartners (US)
- Montgomery County Community College (US)
Publication Details
- Journal
- JAMA
- Published
- 2026-01-08
- DOI
- https://doi.org/10.1001/jama.2025.23452
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 0.00